[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350197-105":59,"doc-detail-350197-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","chd1l-promotes-testicular-cancer-progression-through-epigenetic-activation-of-the-cxcr6pi3kakt-pathway","CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway","","Testicular cancer is a common malignancy in young men, and therapeutic options for metastatic or refractory disease remain limited. This study investigates how chromatin remodeling contributes to tumor progression by focusing on CHD1L. Expression and clinical relevance were assessed using immunohistochemistry and TCGA transcriptomic analyses. Functional experiments including RNA sequencing and ATAC-seq evaluated mechanisms and biological effects, while xenograft models validated tumor-promoting activity. CHD1L overexpression correlated with advanced stage and immune exclusion, enhanced proliferation, migration, and invasion, and activated PI3K/AKT via epigenetic upregulation of CXCR6 through H3K9me3 demethylation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chd1l-promotes-testicular-cancer-progression-through-epigenetic-activation-of-the-cxcr6pi3kakt-pathway/350197/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chd1l-promotes-testicular-cancer-progression-through-epigenetic-activation-of-the-cxcr6pi3kakt-pathway/350197.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this study?","Question",{"text":112,"@type":113},"To clarify the oncogenic and epigenetic functions of CHD1L in testicular cancer and to define downstream pathways that drive progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers evaluate CHD1L relevance in patient data?",{"text":117,"@type":113},"They used immunohistochemistry and TCGA transcriptomic analyses to measure CHD1L expression and relate it to clinical features and immune patterns.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links CHD1L to tumor progression?",{"text":121,"@type":113},"CHD1L promotes CXCR6 transcription through H3K9me3 demethylation, which activates the PI3K/AKT signaling pathway and supports malignant phenotypes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350197,1790176978,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway  \nYang Zhao3,5, Hao Yan4,5, Xinda Chen1, Xiaolin Zhang1, Mujun Lu1􀀍 & Ming Zhang1,2􀀍  \nTesticular cancer is the most common malignancy in young men, and treatment options for metastatic or refractory disease remain limited. Chromatin remodeling plays a critical role in tumorigenesis, yet its contribution to testicular cancer progression is poorly understood. This study aimed to elucidate the oncogenic and epigenetic functions of chromodomain helicase DNA-binding protein 1-like (CHD1L) in testicular cancer. Immunohistochemistry and TCGA transcriptomic analyses were performed to assess CHD1L expression and clinical relevance. Functional assays, RNA sequencing, andATAC-seq were conducted to explore its biological effects and regulatory mechanisms. In vivo xenograft models were used to validate tumor-promoting activity. CHD1L was markedly overexpressed in testicular cancer tissues and correlated with advanced pathological stage. High CHD1L expression was correlated with immune-infiltration patterns indicative of immune exclusion, including increased Treg/Th2 signatures and reduced cytotoxic T-cell activity based on TCGA analyses. Functional studies revealed that CHD1L enhanced cell proliferation, migration, and invasion both in vitro and in vivo. Integrative multi-omics analyses identified CXCR6 as a direct downstream effector ofCHD1L. Mechanistically, CHD1L promoted CXCR6 transcription through H3K9me3 demethylation, thereby activating the PI3K/ AKT signaling pathway. CHD1L drives testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT axis and immune modulation. These findings highlight CHD1L as a potential therapeutic target for advanced or treatment-resistant testicular cancer.  \nKeywords Testicular cancer, CHD1L, CXCR6, Tumor progression, Immune microenvironment  \nTesticular cancer is the most common malignant solid tumor among young men, with a steadily increasing incidence since the mid-20th century1. In 2020 alone, over 70,000 new cases were reported globally2,3. The vast majority of testicular tumors originate from germ cells and can be classified into seminomas and nonseminomas4,5. Although these subtypes differ significantly in their histopathological characteristics, clinical management, and prognostic outcomes, they both retain features reminiscent of primordial germ cells in terms of immunophenotype. Seminomas are frequently diagnosed at an early stage; however, approximately one-third of patients present with metastatic disease at the time of diagnosis6. The prognosis of seminoma varies significantly by disease stage. While patients with localized disease have near-perfect survival, those with regional or distant metastases face reduced 5-year survival rates of 92% and 85%, respectively7.  \nCisplatin-based chemotherapy remains the cornerstone of first-line treatment for testicular cancer and has achieved substantial success when combined with agents such as etoposide and bleomycin8. Despite its efficacy, treatment-associated toxicities—including nephrotoxicity, hepatotoxicity, and neurotoxicity—can limit its broader application, particularly in younger patients who face long-term treatment sequelae9. Moreover, patients who develop resistance to cisplatin often have limited options, with second-line regimens such as vinblastine plus ifosfamide or high-dose chemotherapy followed by stem cell transplantation offering no clear superiority10.  \n1Department of Urology and Andrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 2Jiading Branch of Renji Hospital, Jiading District Central Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai, China. 3Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 4Depart","cbCail4FZ4yvz5GX","https://ap.wps.com/l/cbCail4FZ4yvz5GX","pdf",5482104,15,"English","# Study rationale and background\n## Clinical challenge and treatment limitations\n## Epigenetic dysregulation in testicular cancer\n# CHD1L and mechanistic investigation\n## CHD1L as an epigenetic regulator and oncogenic driver\n## Experimental approach and validation\n# Key findings and therapeutic implications\n## CHD1L expression, immune patterns, and tumor phenotypes\n## CXCR6 activation and PI3K/AKT signaling pathway","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"To clarify the oncogenic and epigenetic functions of CHD1L in testicular cancer and to define downstream pathways that drive progression.\"},{\"question\":\"How did the researchers evaluate CHD1L relevance in patient data?\",\"answer\":\"They used immunohistochemistry and TCGA transcriptomic analyses to measure CHD1L expression and relate it to clinical features and immune patterns.\"},{\"question\":\"What mechanism links CHD1L to tumor progression?\",\"answer\":\"CHD1L promotes CXCR6 transcription through H3K9me3 demethylation, which activates the PI3K/AKT signaling pathway and supports malignant phenotypes.\"}]","CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway | PDF",1790087668,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/beeb58abc73c79eab1f40fa691b70109.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/793c126fb0540d99f50775ddc45fff0f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3182dd08e9153bc2e207a7ef7fdaf742.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9af3a3ce4057f7d65a3589a4769b827c.webp",980,1287]